Could a novel small molecule slow or reverse the effects of Duchenne muscular dystrophy?

In a new study published in The FASEB Journal, investigators demonstrated the potential of a molecule that may help overcome some of the devastating symptoms of Duchenne muscular dystrophy (DMD), the most common life-limiting congenital neuromuscular disorder. The agent promotes the activity of AMP-activated protein kinase (AMPK), an important fuel-sensing enzyme that is present in all mammalian cells.

Leave A Comment

Your email address will not be published. Required fields are marked *